Exact Sciences | EXAS




Peers Price Chg Day Year Date
Agilent 148.69 -3.03 -2.00% 11.75% Feb/03
Becton, Dickinson and Co. 247.70 -0.06 -0.02% 5.37% Feb/03
Bio-Rad Laboratories 353.10 -8.30 -2.30% 7.34% Feb/03
Bruker 56.71 -1.44 -2.48% -21.03% Feb/03
Charles River Laboratories 161.74 -3.12 -1.89% -26.33% Feb/03
Danaher 214.15 -8.39 -3.77% -12.88% Feb/03
Exact Sciences 55.24 -0.81 -1.45% -11.53% Feb/03
Hologic 71.72 -0.42 -0.58% -0.44% Feb/03
Illumina 131.10 -1.64 -1.24% -7.83% Feb/03
Mettler Toledo International 1,344.22 -20.91 -1.53% 9.82% Feb/03
Myriad Genetics 12.77 0.10 0.79% -41.56% Feb/03
Revvity 123.75 -2.32 -1.84% 13.26% Feb/03
Quidel 42.53 -0.93 -2.14% -37.28% Feb/03
Repligen 159.87 -6.34 -3.81% -18.48% Feb/03
STAAR Surgical 23.38 -0.81 -3.35% -15.50% Feb/03
Bio Techne 72.01 -1.56 -2.12% 7.85% Feb/03
Thermo Fisher Scientific 593.43 -4.91 -0.82% 7.58% Feb/03
Veracyte 45.06 -0.42 -0.92% 83.77% Feb/03
Waters 411.51 -4.23 -1.02% 26.68% Feb/03

Indexes Price Day Year Date
USND 19392 -235.49 -1.20% 24.33% Feb/03
US2000 2258 -29.28 -1.28% 16.58% Feb/03

Exact Sciences traded at $55.24 this Monday February 3rd, decreasing $0.81 or 1.45 percent since the previous trading session. Looking back, over the last four weeks, Exact Sciences lost 4.43 percent. Over the last 12 months, its price fell by 11.53 percent. Looking ahead, we forecast Exact Sciences to be priced at 55.28 by the end of this quarter and at 53.02 in one year, according to Trading Economics global macro models projections and analysts expectations.

Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.